Dobutamine

This classification denotes an adrenergic agent with the molecular formula C18H23NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3S12J47372, chemically known as 1,2-benzenediol, 4-(2-((3-(4-hydroxyphenyl)-1-methylpropyl)amino)ethyl)-, (+-)- but generally known as dobutamine, which bears US NIH Compound Identifier 36811. European Medicines Agency schedules Dobutamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06343MIG. The term DOBUTAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, No. 10 1973, List 13). World Health Organization schedules dobutamine in its Anatomical Therapeutic Chemical (ATC) Classification. DOBUTAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule dobutamine under HS 29222900 and SITC 51462. As of Q4 2014, DOBUTAMINE remains the US FDA Preferred Term for this commodity. Dobutamine bears US NLM identifiers UMLS ID C0012963 and NCI Concept Code C61733. SMILES: OC1CC(CCNC(CCC2CCC(O)CC2)C)CCC1O.